Abstract
Introduction
Nontuberculous mycobacteria (NTM) are increasingly recognised as causative agents of opportunistic infections in humans for which effective treatment is challenging. There is very little information on the prevalence of NTM drug resistance in Poland. This study was aimed to evaluate the susceptibility to antibiotics of NTM, originally isolated from diseased ornamental fish.
Material and Methods
A total of 99 isolates were studied, 50 of them rapidly growing mycobacteria (RGM) (among which three-quarters were Mycobacterium chelonae, M. peregrinum, and M. fortuitum and the rest M. neoaurum, M. septicum, M. abscessus, M. mucogenicum, M. salmoniphilum, M saopaulense, and M. senegalense). The other 49 were slowly growing mycobacteria (SGM) isolates (among which only one was M. szulgai and the bulk M. marinum and M. gordonae). Minimum inhibitory concentrations for amikacin (AMK), kanamycin (KAN), tobramycin (TOB), doxycycline (DOX), ciprofloxacin (CIP), clarithromycin (CLR), sulfamethoxazole (SMX), isoniazid (INH) and rifampicin (RMP) were determined.
Results
The majority of the isolates were susceptible to KAN (95.95%: RGM 46.46% and SGM 49.49%), AMK (94.94%: RGM 45.45% and SGM 49.49%), CLR (83.83%: RGM 36.36% and SGM 47.47%), SMX (79.79%: RGM 30.30% and SMG 49.49%), CIP (65.65%: RGM 24.24% and SGM 41.41%), and DOX (55.55%: RGM 9.06% and SGM 46.46%). The majority were resistant to INH (98.98%: RGM 50.50% and SGM 48.48%) and RMP (96.96%: RGM 50.50% and SGM 46.46%).
Conclusion
The drug sensitivity of NTM varies from species to species. KAN, AMK, CLR and SMX were the most active against RGM isolates, and these same four plus DOX and CIP were the best drugs against SGM isolates.
Keywords: Mycobacterium spp, antimicrobial susceptibility, minimum inhibitory concentration, fish
Introduction
Fish mycobacteriosis is a chronic progressive disease caused by several species of the Mycobacterium genus. Mycobacterial species are capable of causing serious diseases in most vertebrates, including humans (28), and infect a wide range of tissue and organ types, with pulmonary infections being the most frequent (57). According to the List of Prokaryotic Names with Standing in Nomenclature, there are over 150 recognised species of mycobacteria (42), all of which other than those in the M. tuberculosis complex and M. leprae are nontuberculous mycobacteria (NTM), also known as environmental mycobacteria, atypical mycobacteria and mycobactaria other than tuberculosis (MOTT). These are generally free-living organisms ubiquitous in the environment and are known to infect a number of aquatic animals, including fish. The host range of this disease is correspondingly broad and includes over 150 species of both marine and freshwater ornamental fish (e.g. Astronotus ocellatus, Carassius auratus, Colisa lalia, Cyprinus carpio subsp. haematopterus, Danio rerio, Helostoma temminckii, Hyphessobrycon serape, Labidochromis caeruleus, Microgeophagus ramirezi, Paracheirodon innesi, Poecilia reticulata, Symphysodon discus, Trichogaster lalius, Xiphophorus helleri and X. maculatus) (15, 19, 23, 31, 44, 45). The most common NTM pathogens of fish include M. marinum, M. fortuitum, M. peregrinum and M. chelonae. Other species isolated from fish include M. abscessus, M. arupense, M. avium, M. chesapeaki, M. conceptionense, M. flavescens, M. gordonae, M. haemophilum, M. kansasii, M. montefiorense, M. mucogenicum, M. neoaurum, M. nonchromogenicum, M. parascrofulaceum, M. porcinum, M. pseudoshottsii, M. salmoniphilum, M. saopaulense, M. scrofulaceum, M. senegalense, M. septicum, M. shimoidei, M. shottsii, M. simiae, M. terrae, M. szulgai, M. triviale, M. triplex, M. ulcerans and M. xenopi (18, 23, 34, 41, 43, 44, 45). In recent years, human nontuberculous mycobacterial infections and diseases have significantly increased (32). There are approximately 30 NTM that are pathogenic to humans, who commonly acquire infections if they are aquarium staff and tropical fish breeders.
The clinical signs of fish mycobacteriosis are nonspecific and include dermal ulceration, scale loss, pigmentary changes, abnormal behaviour, spinal defects, and emaciation. Ascites and granulomas may appear in all internal organs, e.g. the kidneys, liver and spleen (17). Bacterial species such as M. fortuitum, M. marinum, M. smegmatis, M. flavescens, M. peregrinum and M. chelonae, which are well-known pathogens in fish and humans, have been isolated from apparently healthy fish (23, 50). Mycobacterial infections in fish are a risk factor for the human population; nevertheless, relatively few studies have investigated large collections of ornamental fish for the presence of mycobacteria (26, 31, 34, 44).
Regarding food fish rather than ornamental fish and antimycobacterial therapy rather than mycobacterial presence, Kawakami and Kusuda (29) reported that rifampicin, streptomycin, and erythromycin were effective in reducing mortality associated with Mycobacterium spp. in cultured yellowtail (Seriola quinqueradiata). However, there are no treatments for mycobacteriosis in cultured food fish approved by the US Food and Drug Administration, nor are there any unapproved products which have been proven effective in application in the field. If antibiotics are to be used in fish mycobacteriosis treatment, their appropriacy must be validated in terms of the benefit against the risk, because the development and spread of antimicrobial resistance has become a global public health problem that is impacted by both human and non-human antimicrobial usage (37, 65). In this study, the drug susceptibility of 99 isolates of Mycobacterium spp. isolated from diseased ornamental fish to nine antibiotics was investigated.
Material and Methods
Bacterial strains and growth conditions. The study was conducted on 99 NTM strains originally isolated from diseased ornamental fish between January 2015 and December 2016 in the bacteriology laboratory of the Department of Fish Diseases and Biology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Poland. The atypical mycobacteria studied were as follows: M. abscessus (1 isolate), M. chelonae (16 isolates), M. fortuitum (10 isolates), M. gordonae (15 isolates), M. marinum (33 isolates), M. mucogenicum (1 isolate), M. neoaurum (2 isolates), M. peregrinum (12 isolates), M. salmoniphilum (1 isolate), M. saopaulense (1 isolate), M. senegalense (4 isolates), M. septicum (2 isolates), and M. szulgai (1 isolate). The strains of mycobacteria were identified on the basis of molecular characteristics as described previously (44). After successful identification, the strains were stored at −80°C in Youmans broth supplemented with 20% foetal bovine serum until the minimum inhibitory concentrations (MICs) were determined. Mycobacterium marinum ATCC 927 and M. smegmatis ATCC 19420 were used as reference strains, and M. peregrinum ATCC 700686 was used as a quality control strain in the antimicrobial susceptibility tests. Mycobacteria were grown in Middlebrook 7H9 broth for 3 to 5 days, and the culture suspension was adjusted with additional sterile distilled water to equal a McFarland 1.0 turbidity standard (approximately 108 CFU per mL) as described by Aubry et al. (3).
Antimicrobial agents and chemicals. Lyophilisates of eight antimicrobial agents, i.e. amikacin (AMK), ciprofloxacin (CIP), clarithromycin (CLR), doxycycline (DOX), isoniazid (INH), rifampicin (RMP), sulfamethoxazole (SMX) and tobramycin (TOB), were purchased from Sigma-Aldrich Company (St Louis, MO, USA), while the ninth lyophilisate, kanamycin (KAN), was purchased from A&A Biotechnology (Gdynia, Poland). Cation-adjusted Mueller–Hinton broth (CA-MHB) and albumin, dextrose and catalase (ADC) supplement were supplied by Difco (Detroit, MI). Resazurin was ordered from Sigma-Aldrich (St. Louis, MO, USA). All antibiotic solutions were prepared before the day of the experiment and stored at −70°C.
Determination of minimum inhibitory concentration. The MICs of each antimicrobial were determined by the CA-MHB microdilution method, as recommended by the Chemical and Laboratory Standards Institute (CLSI), using 96-well plates. The suspensions of mycobacteria for a resazurin microtitre assay were prepared from Lowenstein–Jensen subcultures. The inocula were adjusted with sterile distilled water to a turbidity equivalent to that of a 1.0 McFarland standard, and the suspensions were then diluted (1:200) using CA-MHB for rapidly growing mycobacteria (RGM) or CA-MHB + 5% ADC supplement (CA-MHB-S) for slowly growing mycobacteria (SGM). The antibiotics were serially diluted twofold in 100 μL of CA-MHB or CA-MHB-S. Each well of a sterile plate was inoculated with 100 μL of mycobacteria suspension, and 100 μL of serial twofold dilutions of the agent was added to each well. A drug-free growth control and a mycobacteria-free sterility control aliquot of the medium were included in each plate. If the microbial growth in the control sample was sufficient, the MICs were measured on day 3. Otherwise, the incubation period was extended, and the MICs were measured on day 4 or 5. The MICs of all antibiotics except for clarithromycin were determined after 3 days (for RGM) or after 4, 5 or 7 days (for SGM) of incubation at 37°C. Plates with M. marinum, M. chelonae and M. salmoniphilum were incubated at 30°C. Extended incubation of plates for clarithromycin was performed as described by Nash et al. (39), with successive readings after 5, 7, 9, and 14 days. After incubation, resazurin at 0.01 g/100 mL was added to each well, and the plates were incubated a second time for 24 h. Each test was performed in triplicate. A colour change from blue (the oxidised state) to pink (the reduced state) indicated bacterial growth. The MIC was defined as the lowest concentration of the drug that prevented this change in colour. The MIC90 and MIC50 values were defined as concentrations that inhibited 90% and 50% of the isolates, respectively. Susceptibility was evaluated according to the CLSI (12, 13) and WHO (66) breakpoint recommendations (Table 1).
Table 1.
MIC breakpoints used for categorisation of susceptibility of RGM and SGM to nine antimicrobial agents
Antimicrobial agent | Range (μg/mL) | MIC breakpoints (μg/mL) |
|||||
---|---|---|---|---|---|---|---|
RGM |
SGM |
||||||
S | I | R | S | I | R | ||
AMK | 1–128 | ≤16 | 32 | ≥64 | - | - | >32 |
KAN | 1–64 | ≤16 | 32 | ≥64 | - | - | >32 |
TOB | 1–64 | ≤1 | 2–4 | ≥8 | - | - | >4 |
DOX | 0.25–32 | ≤2 | 4 | ≥8 | ≤2 | 4 | ≥8 |
CLR | 0.25–32 | ≤2 | 4 | ≥8 | ≤8 | 16 | ≥32 |
CIP | 0.125–16 | ≤1 | 2 | ≥4 | - | - | >2 |
SMX | 1–64 | ≤32 | - | ≥64 | ≤32 | - | ≥64 |
RMP | 0.25–64 | - | - | >1 | - | - | >1 |
INH | 1–64 | - | - | ≥5 | - | - | ≥5 |
MIC – minimum inhibitory concentration; RGM – rapidly growing mycobacteria; SGM – slowly growing mycobacteria; S – susceptible; I – intermediate; R – resistant; AMK – amikacin; KAN – kanamycin; TOB – tobramycin; DOX – doxycycline; CLR – clarithromycin; CIP – ciprofloxacin; SMX – sulfamethoxazole; RMP – rifampicin; INH – isoniazid
Results
The results of the antimicrobial drug susceptibility tests are shown in Table 2 and are presented in terms of resistance, intermediate resistance and susceptibility.
Table 2.
Antimicrobial resistance or susceptibility determined by microdilution
NTM species (number of isolates tested) | Resistant (R) or susceptible (S) | Percentage of strains resistant or susceptible for each antimicrobial agent | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Amikacin | Kanamycin | Tobramycin | Doxycycline | Clarithromycin | Ciprofloxacin | Sulfamethoxazole | Rifampicin | Isoniazid | ||
M. abscessus (n = 1) | R | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | ||||
I | 100.00 | |||||||||
S | 100.00 | 100.00 | 100.00 | |||||||
M. chelonae (n = 16) | R | 6.25 | 43.75 | 100.00 | 6.25 | 100.00 | 100.00 | 100.00 | 100.00 | |
I | 12.50 | 12.50 | 50.00 | |||||||
S | 81.25 | 87.50 | 6.25 | 93.75 | ||||||
M. fortuitum (n = 10) | R | 10.00 | 100.00 | 90.00 | 50.00 | 10.00 | 10.00 | 100.00 | 100.00 | |
I | 10.00 | 40.00 | ||||||||
S | 90.00 | 90.00 | 10.00 | 10.00 | 90.00 | 90.00 | ||||
M. (n gordonae = 15) | R | 20.00 | 6.67 | 20.00 | 93.33 | 100.00 | ||||
I | 46.67 | |||||||||
S | 100.00 | 100.00 | 33.33 | 100.00 | 93.33 | 80.00 | 100.00 | 6.67 | ||
M. marinum (n = 33) | R | 3.03 | 9.09 | 12.12 | 93.94 | 100.00 | ||||
I | 87.88 | 3.03 | ||||||||
S | 100.00 | 100.00 | 9.09 | 90.91 | 96.97 | 87.88 | 100.00 | 6.06 | ||
M. (n mucogenicum = 1) | R | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | ||||
I | 100.00 | |||||||||
S | 100.00 | 100.00 | 100.00 | |||||||
M. neoaurum (n = 2) | R | 100.00 | 100.00 | |||||||
I | ||||||||||
S | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||
M. peregrinum (n = 12) | R | 8.33 | 8.33 | 8.33 | 66.67 | 8.33 | 8.33 | 100.00 | 100.00 | |
I | 33.33 | 8.33 | 8.33 | |||||||
S | 91.67 | 91.67 | 58.33 | 25.00 | 83.34 | 91.67 | 100.00 | |||
M. salmoniphilum (n = 1) | R | 100.00 | 100.00 | 100.00 | ||||||
I | ||||||||||
S | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | ||||
M. saopaulense (n = 1) | R | 100.00 | 100.00 | 100.00 | 100.00 | |||||
I | 100.00 | 100.00 | ||||||||
S | 100.00 | 100.00 | 100.00 | |||||||
M. senegalense (n = 4) | R | 25.00 | 25.00 | 75.00 | 25.00 | 100.00 | 100.00 | |||
I | 25.00 | 25.00 | ||||||||
S | 100.00 | 100.00 | 75.00 | 75.00 | 75.00 | 75.00 | ||||
M. septicum (n = 2) | R | 50.00 | 100.00 | 100.00 | ||||||
I | 50.00 | 50.00 | ||||||||
S | 100.00 | 100.00 | 100.00 | 100.00 | 50.00 | 100.00 | ||||
M. szulgai (n = 1) | R | 100.00 | 100.00 | 100.00 | ||||||
I | ||||||||||
S | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
NTM – nontuberculous mycobacteria; S – susceptible; I – intermediate; R – resistant
The majority of the isolates were susceptible to KAN (95.95%: RGM 46.46% and SGM 49.49%), AMK (94.94%: RGM 45.45% and SGM 49.49%), CLR (83.83%: RGM 36.36% and SGM 47.47%), SMX (79.79%: RGM 30.30% and SMG 49.49%), CIP (65.65%: RGM 24.24% and SGM 41.41%), and DOX (55.55%: RGM 9.06% and SGM 46.46%). Most of the strains were moderately susceptible to TOB (50.50%: RGM 14.14% and SGM 36.36%) (data not shown). While KAN (92.00%), AMK (90.00%), CLR (72.00%) and SMX (60.00%) were the most active against RGM isolates, AMK (100%), KAN (100%), SMX (100.00%), CLR (95.92%), DOX (93.88%) and CIP (83.67%) were the most effective drugs against SGM isolates (Table 3).
Table 3.
Antibiotic susceptibility profiles of RGM and SGM isolated from diseased fish
Antimicrobial agent | Susceptibility |
|||||
---|---|---|---|---|---|---|
RGM (n = 50) |
SGM (n = 49) |
|||||
S | I | R | S | I | R | |
AMK | 90.00 | 4.00 | 6.00 | 100 | 0.00 | 0.00 |
KAN | 92.00 | 6.00 | 2.00 | 100 | 0.00 | 0.00 |
TOB | 32.00 | 28.00 | 40.00 | 16.33 | 73.47 | 10.20 |
DOX | 18.00 | 4.00 | 78.00 | 93.88 | 0.00 | 6.12 |
CLR | 72.00 | 12.00 | 16.00 | 95.92 | 2.04 | 2.04 |
CIP | 48.00 | 8.00 | 44.00 | 83.67 | 0.00 | 16.33 |
SMX | 60.00 | 0.00 | 40.00 | 100.00 | 0.00 | 0.00 |
RMP | 0.00 | 0.00 | 100.00 | 6.12 | 0.00 | 93.88 |
INH | 0.00 | 0.00 | 100.00 | 2.04 | 0.00 | 97.96 |
RGM – rapidly growing mycobacteria; SGM – slowly growing mycobacteria; S – susceptible; I – intermediate; R – resistant; AMK – amikacin; KAN – kanamycin; TOB – tobramycin; DOX – doxycycline; CLR – clarithromycin; CIP – ciprofloxacin; SMX – sulfamethoxazole; RMP – rifampicin; INH – isoniazid
Almost all of the isolates were resistant to INH (98.98%: RGM 50.50% and SGM 48.48%) and RMP (96.96%: RGM 50.50% and SGM 46.46%) (data not shown). RGM isolates were resistant to RMP (100%), INH (100%), and the greater part of them were resistant to DOX (78.00%), and SGM isolates were resistant to INH (97.96%) and RMP (93.88%) (Table 3).
Discussion
Nontuberculous mycobacteria are known to be ubiquitous in the environment. Mycobacterium marinum, M. chelonae, M. peregrinum, M. gordonae, M. fortuitum, M. abscessus, M. mucogenicum, M. neoaurum, M. septicum, M. senegalense and M. szulgai have been isolated from diseased fish (1, 11, 16, 44, 45, 63, 64) and have been shown to be the causative agents of pulmonary, skin, soft tissue and disseminated diseases in humans (1, 10, 11, 16, 36, 46, 54, 55). As in other countries, in Poland also Kwiatkowska et al. (32) observed an increased frequency of NTM isolated from clinical samples. Several isolates in the present study, namely M. abscessus, M. chelonae, M. fortuitum, M. gordonae, M. marinum, M. mucogenicum, M. neoaurum, M. peregrinum and M. szulgai, were also identified by Kwiatkowska et al. (32) in human clinical samples.
At present, standard therapeutic strategies for treating NTM infections are yet to be laid down. In this study, nine antimicrobial agents were tested against 99 NTM pathogens isolated from diseased ornamental fish (44). The growth of most NTM isolates was inhibited by AMK and KAN, only a few isolates showing a multidrug resistance profile which rendered these antimicrobials ineffective. Similarly, Yakrus et al. (67) also found that only 1 of 75 strains of M. abscessus and M. chelonae was resistant to AMK, and Swenson et al. (53) observed AMK to be most active against M. fortuitum. In the present study, the M. abscessus, M. chelonae, M. fortuitum, M. mucogenicum, M. saopaulense and M. szulgai isolates showed a multidrug resistance profile to at least three different classes of antimicrobials.
Mycobacterium marinum is intrinsically resistant to pyrazinamide and INH. Antibiotic agents that have been shown to be active against M. marinum include CLR, RMP, SMX, ethambutol, tetracyclines, some of the quinolones, and those used in combination therapy, i.e. ethambutol and RMP (27). The MICs of CIP, trimethoprim, azithromycin, telithromycin, quinupristin/dalfopristin, gemifloxacin, ofloxacin, and levofloxacin are above the concentrations usually obtained in vivo, and consequently, M. marinum may be considered resistant to them (5, 7, 47, 60). Chang and Whipps (11) showed that six strains of M. marinum isolated from diseased zebrafish were susceptible to AMK, CLR and RMP. In the present study, the majority of the M. marinum isolates were susceptible to AMK, CLR, KAN, DOX, CIP and SMX, whereas most isolates were resistant to RMP and INH.
There is currently no effective and definitive treatment for M. gordonae infection. Ethambutol, rifabutin, linezolid, CLR and new quinolones are active in vitro as antibiotics, but in vivo data are still insufficient (22, 56). Treatment with RMP, INH, pyrazinamide, and ethambutol was successfully used by Tsankova et al. (56). In a study by Goswami et al. (21), most of the M. gordonae isolates were sensitive to CLR and AMK and resistant to the first-line antitubercular drugs INH, RMP, ethambutol and streptomycin. In the present study, the majority of M. gordonae isolates were susceptible to AMK, KAN, DOX, CLR and CIP and SMX, but resistant to INH and RMP.
Mycobacterium abscessus, M. chelonae, M. salmoniphilum and M. saopaulense are members of the M. chelonae-abscessus complex (35, 40, 53). Natural susceptibility to AMK, cefoxitin and imipenem and resistance to many other chemotherapeutic agents are characteristics of M. abscessus (35). Current treatment recommendations for M. abscessus pulmonary infections include therapy combining two or more intravenous drugs (AMK, tigecycline, imipenem and cefoxitin) with one or two oral antimicrobials, including macrolides, linezolid, clofazimine and, occasionally, a quinolone (38). Almost all M. abscessus strains tested by Shen et al. (51) were found to be resistant to SMX, vancomycin, oxacillin, clindamycin, and all fluoroquinolones, and more than 50% of the isolates were resistant to tetracyclines, carbapenems, and aminoglycosides, except for amikacin. The lowest resistance rates to cefoxitin (10%), azithromycin (10%), AMK (10%), and CLR (20%) (51) were demonstrated by M. abscessus. In this study, M. abscessus was susceptible to AMK, KAN and CLR, and resistant to TOB, DOX, SMX, RMP and INH. These findings are comparable to those described in other studies (14, 35, 43).
Regimens for the treatment of M. chelonae infections may include TOB, CLR, CIP, DOX and AMK. Hatakeyama et al. (25) showed that M. chelonae was susceptible to AMK, TOB, CLR, SMX, imipenem, linezolid and tigecycline. In this study, the majority of the M. chelonae isolates were susceptible to AMK, CLR and KAN, but resistant to DOX, CIP, SMX, RMP and INH.
The antimicrobial pattern of M. saopaulense is characterised by susceptibility to CLR and resistance to DOX, TOB and cefoxitin. Variable results, intermediate or resistant, were obtained with AMK, CIP, minocycline and moxifloxacin (40). In this research, the M. saopaulense isolate was susceptible to AMK, KAN and CLR, and resistant to DOX, SMX, RMP and INH.
Nogueira et al. (40) found that M. salmoniphilum was susceptible to AMK, CLR, and CIP and resistant to DOX, which is consistent with our results finding the test strain to be susceptible to AMK, KAN, TOB, CLR, CIP and SMX, and resistant to DOX, RMP and INH.
Mycobacterium fortuitum, M. peregrinum, M. septicum and M. senegalense are members of the M. fortuitum complex. M. fortuitum isolates are usually susceptible to multiple antimicrobial agents, including AMK, CIP, CLR, DOX, sulphonamides, cefoxitin, and imipenem (6, 53, 61). Hatakeyama et al. (25) showed that M. fortuitum was susceptible to AMK, CIP, moxifloxacin, imipenem, linezolid, meropenem and tigecycline. In our research, most of the M. fortuitum isolates were found to be susceptible to AMK, KAN, CIP and SMX, and resistant to TOB, DOX, RMP and INH. The results of this study correlate well with those of other investigators (33), differing only from those reported by Lee et al. (33), who found strains susceptible to CLR (93%) and DOX (84%).
At present, little information is available on antibiotic activity against M. peregrinum. In a study by Guz et al. (23), test strains of M. peregrinum were found to be susceptible to AMK, ofloxacin and capreomycin, and resistant to RMP, INH, streptomycin, ethambutol, sulfamethoxazole/trimethoprim, clofazimine and erythromycin cyclocarbonate. Santos et al. (48) showed that the new fluoroquinolones with the C8-methoxy group, especially moxifloxacin, exhibit greater activity against this species. In the present study, most strains were susceptible to AMK, KAN, CIP, SMX, CLR and TOB, which correlates well with the results reported by Hatakeyama et al. (25).
Most of the M. septicum strains tested by Lian et al. (36) were found to be susceptible to AMK, CIP, SMX, KAN, ofloxacin and levofloxacin. The strains of M. septicum described by Schinsky et al. (49) were susceptible to AMK, CIP, DOX, SMX, TOB, KAN, amoxicillin-clavulanate, erythromycin, imipenem, minocycline, trimethoprim-sulfamethoxazole, vancomycin, gentamicin and neomycin but resistant to ampicillin, cefamandole, cefotaxime, ceftriaxone and streptomycin. Go et al. (20) found M. septicum isolates to be susceptible to AMK, CIP, imipenem, linezolid, moxifloxacin, and trimethoprim-sulfamethoxazole but universally resistant to CLR and DOX. In our research, the M. septicum isolates were susceptible to AMK, KAN, TOB, CLR and SMX, but resistant to RMP and INH.
Talavilikar et al. (54) showed that M. senegalense was susceptible to AMK, CLR, CIP, DOX, cefoxitin, imipenem and trimethoprim/sulfamethoxazole, which is consistent with previously published results (2, 62). In the present study, most M. senegalense isolates were susceptible to AMK, KAN, TOB, DOX, CLR and SMX and resistant to RMP and INH.
The majority of M. neoaurum isolates tested by Brown-Elliott et al. (9) were susceptible to AMK, TOB, CIP, DOX, SMX, cefoxitin, gatifloxacin, imipenem, linezolid, moxifloxacin, tigecycline and trimethoprim/ sulfamethoxazole. In our research, the M. neoaurum isolates were susceptible to AMK, KAN, TOB, DOX, CLR, CIP, SMX and INH and resistant to RMP and INH.
Rapidly growing mycobacteria are usually resistant to standard antimicrobial therapy, but M. mucogenicum is generally more susceptible to antimicrobials. Isolates of this species are susceptible to most antibacterial agents, i.e. AMK, KAN, CLR, CIP, imipenem, cefoxitin, linezolid, cephalothin, polymyxin B, and fluoroquinolones, but like other RGM, they are resistant to first-line antitubercular agents, i.e. RMP, INH, and pyrazinamide (8, 24, 52). Han et al. (24) reported that 100% (25/25) of M. mucogenicum isolates were susceptible to AMK, CLR, cefoxitin, imipenem and trimethoprim-sulfamethoxazole. In addition, 88% of isolates were susceptible to CIP, and 67% were susceptible to DOX, whereas 45% of strains were resistant to minocycline. Furthermore, Van Ingen et al. (58) tested 15 M. mucogenicum strains against a panel of 11 antibiotics and found the majority to be susceptible to AMK, CLR, CIP and rifabutin. The current NTM practice guidelines do not explicitly state a specific treatment protocol for M. mucogenicum but do state that most isolates are susceptible to multiple antimicrobial agents, including AMK, CLR, KAN, DOX, quinolones and imipenem (4, 24). In our research, the M. mucogenicum isolate was susceptible to AMK, KAN and SMX but resistant to CIP, RMP and INH.
Isolates of M. szulgai are often susceptible in vitro to most antitubercular agents. The most common regimen includes RMP, ethambutol and macrolides and/or quinolones (59). Lung disease induced by M. szulgai was successfully treated with RMP, CLR and ethambutol by Kempisty et al. (30). In the present study, the M. szulgai isolate was susceptible to AMK, KAN, DOX, CLR, SMX and INH and resistant to RMP, CIP and TOB.
In summary, this study determined the antibiotic susceptibility of ornamental fish mycobacteria. The antimicrobial resistance rate of Mycobacterium spp. isolated from ornamental fish is high and thus needs to be monitored. Tested in this investigation for effect against isolates from diseased fish, KAN, AMK, CLR and SMX were the most inhibitory of rapidly growing mycobacteria, while AMK, KAN, SMX, CLR, DOX and CIP were the most efficacious against slowly growing mycobacteria. Our results confirm that antibiotic-resistant bacteria can be found in fish, which has potential consequences for public health. Consequently, continued monitoring of Mycobacterium spp. for antibiotic resistance should be performed in ornamental fish to help to establish strategies for the treatment of mycobacteriosis.
Footnotes
Conflict of Interest
Conflict of Interests Statement: The authors declare that there is no conflict of interests regarding the publication of this article.
Financial Disclosure Statement: The study was financed by the statutory activity of the University of Life Sciences in Lublin.
Animal Rights Statement: None required.
References
- 1.Abalain-Colloc M.L., Guillerm D., Saläun M., Gouriou S., Vincent V., Picard B.. Mycobacterium szulgai isolated from a patient, a tropical fish and aquarium water. Eur J Clin Microbiol Infect Dis. 2003;22:768–769. doi: 10.1007/s10096-003-1036-x. [DOI] [PubMed] [Google Scholar]
- 2.Adékambi T., Stein A., Carvajal J., Raoult D., Drancourt M.. Description of Mycobacterium conceptionense sp. nov., a Mycobacerium fortuitum group organism isolated from a posttraumatic osteitis inflammation. J Clin Microbiol. 2006;44:1268–1273. doi: 10.1128/JCM.44.4.1268-1273.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Aubry A., Jarlier V., Escolano S., Truffot-Pernot C., Cambau E.. Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob Agents Chemother. 2000;44:3133–3136. doi: 10.1128/aac.44.11.3133-3136.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Basnet S., Mir I., Dhital R., Basnet G., Patel N.. Mycobacterium mucogenicum hand infection in an intravenous drug abuser. Case Rep Infect Dis. 2018;1258649:1–3. doi: 10.1155/2018/1258649. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bråbäck M., Riesbeck K., Forsgren A.. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. Antimicrob Agents Chemother. 2002;46:1114–1116. doi: 10.1128/aac.46.4.1114-1116.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Brown B.A., Wallace R.J.Jr., Onyi G.O., De Rosas V., Wallace R.J.III.. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonae-like organisms. Antimicrob Agents Chemother. 1992;36:180–184. doi: 10.1128/aac.36.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Brown-Elliott B.A., Crist C.J., Mann L.B., Wilson R.W., Wallace R.J.Jr.. In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob Agents Chemother. 2003;47:1736–1738. doi: 10.1128/aac.47.5.1736-1738.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Brown-Elliott B.A., Wallace R.J.Jr.. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:716–746. doi: 10.1128/CMR.15.4.716-746.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Brown-Elliott B.A., Wallace R.J.Jr., Petti C.A., Mann L.B., McGlasson M., Chihara S., Smith G.L., Painter P., Hail D., Wilson R., Simmon K.E.. Mycobacterium neoaurum and Mycobacterium bacteremicum sp. nov. as causes of mycobacteremia. J Clin Microbiol. 2010;48:4377–4385. doi: 10.1128/JCM.00853-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Brown-Elliott B.A., Woods G.L.. Antimycobacterial susceptibility testing of nontuberculous mycobacteria. J Clin Microbiol. 2019;57:e00834–19. doi: 10.1128/JCM.00834-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chang C.T., Whipps C.M.. Activity of antibiotics against Mycobacterium species commonly found in laboratory zebrafish. J Aquat Anim Health. 2015;27:88–95. doi: 10.1080/08997659.2015.1007176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Clinical and Laboratory Standards. Institute: M24-A2 Susceptibility Testing of Mycobacteria, Nocardia, and other aerobic actinomycetes; Approved standard–Second Edition. CLSI; Wayne: 2011. [PubMed] [Google Scholar]
- 13.Clinical and Laboratory Standards. Institute: M100-S25 Performance Standards for Antimicrobial Susceptibility Testing; Twenty First Informational Supplement. CLSI; Wayne: 2015. [Google Scholar]
- 14.Colombo R.E., Olivier K.N.. Diagnosis and treatment of infections caused by rapidly growing mycobacteria. Semin Respir Crit Care Med. 2008;29:577–588. doi: 10.1055/s-0028-1085709. [DOI] [PubMed] [Google Scholar]
- 15.Decostere A., Hermans K., Haesebrouck F.. Piscine mycobacteriosis: a literature review covering the agent and the disease it causes in fish and humans. Vet Microbiol. 2004;99:159–166. doi: 10.1016/j.vetmic.2003.07.011. [DOI] [PubMed] [Google Scholar]
- 16.Dibaj R., Shojaei H., Narimani T.. Identification and molecular characterization of mycobacteria isolated from animal sources in a developing country. Acta Trop. 2020;204:105297. doi: 10.1016/j.actatropica.2019.105297. [DOI] [PubMed] [Google Scholar]
- 17.Gauthier D.T., Rhodes M.W.. Mycobacteriosis in fishes: A review. Vet J. 2009;180:33–47. doi: 10.1016/j.tvjl.2008.05.012. [DOI] [PubMed] [Google Scholar]
- 18.Gcebe N., Michel A.L., Hlokwe T.M.. Non-tuberculous Mycobacterium species causing mycobacteriosis in farmed aquatic animals of South Africa. BMC Microbiol. 2018;18:32. doi: 10.1186/s12866-018-1177-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Giavenni R., Finazzi M., Poli G., Grimaldi E.. Tuberculosis in marine tropical fishes in an aquarium. J Wildl Dis. 1980;16:161–168. doi: 10.7589/0090-3558-16.2.161. [DOI] [PubMed] [Google Scholar]
- 20.Go J.R., Wengenack N.L., Abu Saleh O.M., Corsini Campioli C., Deml S.M., Wilson J.W.. Mycobacterium septicum: a 6-year clinical experience from a Tertiary Hospital and Reference Laboratory. J Clin Microbiol. 2020;58:e02091–20. doi: 10.1128/JCM.02091-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Goswami B., Narang P., Mishra P.S., Narang R., Narang U., Mendiratta D.K.. Drug susceptibility of rapid and slow growing non-tuberculous mycobacteria isolated from symptomatics for pulmonary tuberculosis, Central India. Indian J Med Microbiol. 2016;34:442–447. doi: 10.4103/0255-0857.195375. [DOI] [PubMed] [Google Scholar]
- 22.Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., Holland S.M., Horsburgh R., Huitt G., Iademarco M.F., Iseman M., Olivier K., Ruoss S., von Reyn C.F., Wallace R.J.Jr., Winthrop K.. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416. doi: 10.1164/rccm.200604-571ST. [DOI] [PubMed] [Google Scholar]
- 23.Guz L., Grądzki Z., Krajewska M., Lipiec M., Zabost A., Augustynowicz-Kopeć E., Zwolska Z., Szulowski K.. Occurrence and antimicrobial susceptibility of Mycobacterium peregrinum in ornamental fish. Bull Vet Inst Pulawy. 2013;57:489–492. doi: 10.2478/bvip-2013-0085. [DOI] [Google Scholar]
- 24.Han X.Y., Dé I., Jacobson K.L.. Rapidly growing mycobacteria: clinical and microbiologic studies of 115 cases. Am J Clin Pathol. 2007;128:612–621. doi: 10.1309/1KB2GKYT1BUEYLB5. [DOI] [PubMed] [Google Scholar]
- 25.Hatakeyama S., Ohama Y., Okazaki M., Nukui Y., Moriya K.. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan. BMC Infect Dis. 2017;17:197. doi: 10.1186/s12879-017-2298-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Hongslo T., Jansson E.. Occurrence of different species of mycobacteria in aquarium fish from Swedish pet-shops. Bull Eur Assoc Fish Pathol. 2014;34:78–89. [Google Scholar]
- 27.Huminer D., Pitlik S.D., Block C., Kaufman L., Amit S., Rosenfeld J.B.. Aquarium-borne Mycobacterium marinum skin infection. Arch Dermatol. 1986;122:698–703. [PubMed] [Google Scholar]
- 28.Jacobs J.M., Stine C.B., Baya A.M., Kent M.L.. A review of mycobacteriosis in marine fish. J Fish Dis. 2009;32:119–130. doi: 10.1111/j.1365-2761.2008.01016.x. [DOI] [PubMed] [Google Scholar]
- 29.Kawakami K., Kusuda R.. Efficacy of rifampicin, streptomycin and erythromycin against experimental Mycobacterium infection in cultured yellowtail (in Japanese) Nippon Suisan Gakk. 1990;56:51–53. doi: 10.2331/suisan.56.51. [DOI] [Google Scholar]
- 30.Kempisty A., Augustynowicz-Kopeć E., Opoka L., Szturmowicz M.. Mycobacterium szulgai lung disease or breast cancer relapse – case report. Antibiotics. 2020;9:482. doi: 10.3390/antibiotics9080482. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kušar D., Zajc U., Jenčič V., Ocepek M., Higgins J., Žolnir-Dovč M., Pate M.. Mycobacteria in aquarium fish: results of a 3-year survey indicate caution required in handling pet-shop fish. J Fish Dis. 2016;40:773–784. doi: 10.1111/jfd.12558. [DOI] [PubMed] [Google Scholar]
- 32.Kwiatkowska S., Augustynowicz-Kopeć E., Korzeniewska-Koseła M., Filipczak D., Gruszczyński P., Zabost A., Klatt M., Sadkowska-Todys M.. Nontuberculous mycobacteria strains isolated from patients between 2013 and 2017 in Poland. Our data with respect to the global trends. Adv Respir Med. 2018;86:291–298. doi: 10.5603/ARM.a2018.0047. [DOI] [PubMed] [Google Scholar]
- 33.Lee S.M., Kim J.M., Jeong J., Park Y.K., Bai G.-H., Lee E.Y., Lee M.K., Chang C.L.. Evaluation of the broth microdilution method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing. J Korean Med Sci. 2007;22:784–790. doi: 10.3346/jkms.2007.22.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Lescenko P., Matlova L., Dvorska L., Bartos M., Vavra O., Navratil S., Novotny L., Pavlik I.. Mycobacterial infection in aquarium fish. Vet Med – Czech. 2003;48:71–78. doi: 10.17221/5752-VETMED. [DOI] [Google Scholar]
- 35.Li G., Lian L.-L., Wan L., Zhang J., Zhao X., Jiang Y., Zhao L.-L., Liu H., Wan K.. Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate alamar blue assay. PloS One. 2013;8:e84065. doi: 10.1371/journal.pone.0084065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Lian L.-L., Deng J., Zhao X., Dong H., Zhang J., Li G., Xiao T., Wu Y., Li Q., Wan K.. The first case of pulmonary disease caused by Mycobacterium septicum in China. Int. J Infect Dis. 2013;17:E352–E354. doi: 10.1016/j.ijid.2012.12.011. [DOI] [PubMed] [Google Scholar]
- 37.Martin A., Paasch F., Docx S., Fissette K., Imperiale B., Ribón W., González L.A., Werngren J., Engström A., Skenders G., Juréen P., Hoffner S., Del Portillo P., Morcillo N., Palomino J.C.. Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis. J Antimicrob Chemother. 2011;66:827–833. doi: 10.1093/jac/dkq527. [DOI] [PubMed] [Google Scholar]
- 38.Meir M., Barkan D.. Alternative and experimental therapies of Mycobacterium abscessus infections. Int J Mol Sci. 2020;21:6793. doi: 10.3390/ijms21186793. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Nash K.A., Brown-Elliott B.A., Wallace R.J.Jr.. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53:1367–1376. doi: 10.1128/AAC.01275-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Nogueira C.L., Whipps C.M., Matsumoto C.K., Chimara E., Droz S., Tortoli E., de Freitas D., Cnockaert M., Palomino J.C., Martin A., Vandamme P., Leão S.C.. Mycobacterium saopaulense sp. nov., a rapidly growing mycobacterium closely related to members of the Mycobacterium chelonae Mycobacterium abscessus group. Int J Syst Evol Microbiol. 2015;65:4403–4409. doi: 10.1099/ijsem.0.000590. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Novotny L., Dvorska L., Lorencova A., Beran V., Pavlik I.. Fish: a potential source of bacterial pathogens for human beings. Vet Med – Czech. 2004;49:343–358. doi: 10.17221/5715-VETMED. [DOI] [Google Scholar]
- 42.Parte A.C., Sardà Carbasse J., Meier-Kolthoff J.P., Reimer L.C., Göker M.. List of Prokaryotic Names with Standing in Nomenclature (LPSN) moves to the DSMZ. Int J Syst Evolut Microbiol. 2020;70:5607–5612. doi: 10.1099/ijsem.0.004332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Petrini B.. Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS. 2006;114:319–328. doi: 10.1111/j.1600-0463.2006.apm_390.x. [DOI] [PubMed] [Google Scholar]
- 44.Puk K., Guz L.. Occurrence of Mycobacterium spp. in ornamental fish. Ann Agric Environ Med. 2020;27:535–539. doi: 10.26444/aaem/114913. [DOI] [PubMed] [Google Scholar]
- 45.Puk K., Banach T., Wawrzyniak A., Adaszek Ł., Ziętek J., Winiarczyk S., Guz L.. Detection of Mycobacterium marinum, M. peregrinum, M. fortuitum and M. abscessus in aquarium fish. J Fish Dis. 2018;41:153–156. doi: 10.1111/jfd.12666. [DOI] [PubMed] [Google Scholar]
- 46.Rakhmawatie M.D., Wibawa T., Lisdiyanti P., Pratiwi W.R.. Mustofa: Evaluation of crystal violet decolorization assay and resazurin microplate assay for antimycobacterial screening. Helion. 2019;5:e02263. doi: 10.1016/j.heliyon.2019.e02263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Rhomberg P.R., Jones R.N.. In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn Microbiol Infect Dis. 2002;42:145–147. doi: 10.1016/s0732-8893(01)00332-7. [DOI] [PubMed] [Google Scholar]
- 48.Santos A., Cremades R., Rodriguez J.C., Ruiz M., Royo G., Garcia-Pachon E.. Mycobacterium peregrinum: bactericidal activity of antibiotics alone and in combination. J Infect Chemother. 2008;14:262–263. doi: 10.1007/s10156-008-0611-6. [DOI] [PubMed] [Google Scholar]
- 49.Schinsky M.F., McNeil M.M., Whitney A.M., Steigerwalt A.G., Lasker B.A., Floyd M.M., Hogg G.G., Brenner D.J., Brown J.M.. Mycobacterium septicum sp. nov., a new rapidly growing species associated with catheter-related bacteraemia. Int J Syst Evol Microbiol. 2000;50:575–581. doi: 10.1099/00207713-50-2-575. [DOI] [PubMed] [Google Scholar]
- 50.Seyfahmadi M., Moaddab S.R., Sabokbar A.. Identification of mycobacteria from unhealthy and apparently healthy aquarium fish using both conventional and PCR analyses of hsp65 gene. Thai J Vet Med. 2017;47:571–578. [Google Scholar]
- 51.Shen Y., Wang X., Jin J., Wu J., Zhang X., Chen J., Zhang W.. In vitro susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum isolates to 30 antibiotics. BioMed Res Int. 2018;4902941:1–10. doi: 10.1155/2018/4902941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Springer B., Böttger E.C., Kirschner P., Wallace R.J.Jr.. Phylogeny of the Mycobacterium chelonae-like organism based on partial sequencing of the 16S rRNA gene and proposal of Mycobacterium mucogenicum sp. nov. Int J Syst Bacteriol. 1995;45:262–267. doi: 10.1099/00207713-45-2-262. [DOI] [PubMed] [Google Scholar]
- 53.Swenson J.M., Wallace R.J.Jr., Silcox V.A., Thornsberry C.. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985;28:807–811. doi: 10.1128/aac.28.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Talavlikar R., Carson J., Meatherill B., Desai S., Sharma M., Shandro C., Tyrrell G.J., Kuhn S.. Mycobacterium senegalense tissue infection in a child after fish tank exposure. Can J Infect Dis Med Microbiol. 2011;22:101–103. doi: 10.1155/2011/206532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Tortoli E., Besozzi G., Lacchini C., Penati V., Simonetti M.T., Emler S.. Pulmonary infection due to Mycobacterium szulgai: case report and review of the literature. Eur Respir J. 1998;11:975–977. doi: 10.1183/09031936.98.11040975. [DOI] [PubMed] [Google Scholar]
- 56.Tsankova G., Kaludova V., Todorova T., Ermenlieva N., Georgieva E.. Nontuberculous tuberculosis caused by Mycobacterium gordonae – clinical case report. J IMAB. 2015;21:856–858. doi: 10.5272/jimab.2015213.856. [DOI] [Google Scholar]
- 57.Van Ingen J., Griffith D.E., Aksamit T.R., Wagner D.. Pulmonary diseases caused by non-tuberculous mycobacteria. Eur Respir Monogr. 2012;58:25–37. doi: 10.1183/1025448x.10022511. [DOI] [Google Scholar]
- 58.Van Ingen J., van der Laan T., Dekhuijzen R., Boeree M., van Soolingen D.. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in the Netherlands. Int J Antimicrob Agents. 2010;35:169–173. doi: 10.1016/j.ijantimicag.2009.09.023. [DOI] [PubMed] [Google Scholar]
- 59.Van Ingen J., Boeree M.J., de Lange W.C.M., de Haas P.E.W., Dekhuijzen P.N.R., van Soolingen D.. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis. 2008;46:1200–1205. doi: 10.1086/529443. [DOI] [PubMed] [Google Scholar]
- 60.Vera-Cabrera L., Brown-Elliott B.A., Wallace R.J.Jr., Ocampo-Candiani J., Welsh O., Choi S.H., Molina-Torres C.A.. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria. Antimicrob Agents Chemother. 2006;50:4027–4029. doi: 10.1128/AAC.00763-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Wallace R.J.Jr., Brown B.A., Onyi G.. Susceptibilities of M. fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1991;35:773–775. doi: 10.1128/aac.35.4.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Wallace R.J.Jr., Brown-Elliot B.A., Brown J., Steigerwalt A.G., Hall L., Woods G., Cloud J., Mann L., Wilson R., Crist C., Jost K.C.Jr., Byrer D.E., Tang J., Cooper J., Stamenova E., Campbell B., Wolfe J., Turenne C.. Polyphasic characterization reveals that the human pathogen Mycobacterium peregrinum type II belongs to the bovine pathogen species Mycobacterium senegalense. J Clin Microbiol. 2005;43:5925–5935. doi: 10.1128/JCM.43.12.5925-5935.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Watral V., Kent M.L.. Pathogenesis of Mycobacterium spp. in zebrafish (Danio rerio) from research facilities. Comp Biochem Physiol C. 2007;145:55–60. doi: 10.1016/j.cbpc.2006.06.004. [DOI] [PubMed] [Google Scholar]
- 64.Whipps C.M., Lieggi C., Wagner R.. Mycobacteriosis in zebrafish colonies. ILAR Journal. 2012;53:95–105. doi: 10.1093/ilar.53.2.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.World Health Organization. Joint FAO/OIE/WHO Expert workshop on non-human antimicrobial usage and antimicrobial resistance: scientific assessment. WHO; Geneva: 2004. https://apps.who.int/iris/handle/10665/68883 [Google Scholar]
- 66.World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO; Geneva: 2008. https://www.who.int/tb/publications/2008/whohtmtb_2008_392/en [PubMed] [Google Scholar]
- 67.Yakrus M.A., Hernandez S.M., Floyd M.M., Sikes D., Butler W.R., Metchock B.. Comparison of methods for identification of Mycobacterium abscessus and M. chelonae isolates. J Clin Microbiol. 2001;39:4103–4110. doi: 10.1128/JCM.39.11.4103-4110.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]